• Alzinova submitted its Phase 2a ADVANCE study of Alzheimer’s vaccine ALZ-101 for US ethics review by Advarra, covering seven trial sites.
• The study targets approximately 120 participants with early Alzheimer’s disease; first enrollment is planned around the turn of 2026/2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzinova AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.